Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory Round-Up: Drug Review Profiles From 2012

Executive Summary

Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile. If you do not have access, contact customer care at 1-800-332-2181 for a free copy of any of these articles.

Advertisement

Related Content

Erivedge Efficacy Overcomes Limitations Of Single-Arm Study
To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management
Bydureon Approval Provides Lesson In Clinical Data Requirements For Biosimilars
Bydureon Review Documents Paint An Unflattering Portrait Of Amylin
Secondary Endpoints Backed Kalydeco’s Efficacy, Despite Lack Of Correlation With Pulmonary Function
Kalydeco Passed FDA’s Approval Test With The Help Of A Failed Study
Persistence, Secondary Endpoints Helped Shire Get FDA Nod For Firazyr Novel PRO
Multiple Aspirin Dose Analyses Reassured FDA On Brilinta’s U.S. Efficacy
Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience
Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

Topics

Advertisement
UsernamePublicRestriction

Register

PS055090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel